Kidney drug developer Unicycive Therapeutics' Q3 net loss widens on launch costs
UNCY•
UNCY•Unicycive Therapeutics said its third-quarter net loss widened as commercial launch expenses increased. It ended the quarter with $59 million in cash and expects its runway to extend beyond 2027; the FDA set a March 25, 2027, decision date for its OLC application resubmission.
Unicycive attributed its wider third-quarter net loss to higher commercial launch expenses for OLC. Loss per share was $0.25. Research and development expense fell as development costs decreased, while general and administrative expense rose with higher stock-based compensation, labor costs and $1.4 million in launch preparation costs.
The company ended the quarter with $59 million in cash and expects its cash runway to extend beyond 2027. The FDA accepted OLC's NDA resubmission and set a decision date of March 25, 2027. Unicycive is preparing for a potential commercial launch, and said recent CMS rule changes may support favorable reimbursement if OLC is approved.